Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

1. Management of osteoporosis and the prevention of fragility fractures

Management of osteoporosis and the prevention of fragility fractures Management of osteoporosis and the prevention of fragility fractures A national clinical guideline First published March 2015 Revised June 2020 Revised January 2021 SIGN142Key to evidence statements and recommendations Levels of evidence 1 ++ High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 1 + Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias 1 – Meta (...) used by Scottish Intercollegiate Guidelines Network to produce clinical guidelines. The accreditation term is valid until 30 June 2020 and is applicable to guidance produced using the processes described in SIGN 50: a guideline developer’s handbook, 2019 edition (https://www.sign.ac.uk/assets/sign50_2019.pdf). More information on accreditation can be viewed at www.nice.org.uk/accreditationScottish Intercollegiate Guidelines Network Management of osteoporosis and the prevention of fragility

2021 SIGN

2. Romosozumab (osteoporosis) - Addendum to Commission A20-24

Romosozumab (osteoporosis) - Addendum to Commission A20-24 1 Translation of addendum A20-67 Romosozumab (Osteoporose) – Addendum zum Auftrag A20-24 (Version 1.0; Status: 14 August 2020). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 14 August 2020 1.0 Commission: A20-67 Version: Status: IQWiG Reports – Commission No. A20-67 Romosozumab (osteoporosis (...) ) – Addendum to Commission A20-24 1 Addendum A20-67 Version 1.0 Romosozumab – Addendum to Commission A20-24 14 August 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic Romosozumab (osteoporosis) – Addendum to Commission A20-24 Commissioning agency Federal Joint Committee Commission awarded on 28 July 2020 Internal Commission No. A20-67 Address of publisher Institut für Qualität und Wirtschaftlichkeit

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

3. Romosozumab (osteoporosis) - Benefit assessment according to §35a Social Code Book V

Romosozumab (osteoporosis) - Benefit assessment according to §35a Social Code Book V 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Romosozumab (Osteoporose) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 10 June 2020). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. A20-24 Romosozumab (...) (osteoporosis) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A20-24 Version 1.0 Romosozumab (osteoporosis) 10 June 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic Romosozumab (osteoporosis) – Benefit assessment according to §35a Social Code Book V Commissioning agency Federal Joint Committee Commission awarded on 11 March 2020 Internal Commission No. A20

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

4. Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis

Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis ENDOCRINE PRACTICE Vol 26 (Suppl 1) May 2020 1 Copyright © 2020 AACE Clinical Practice Guidelines AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/ AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS— 2020 UPDATE Pauline M. Camacho, MD, FACE 1 ; Steven M. Petak, MD, JD, FACP , FCLM, MACE, CCD 2 ; Neil Binkley, MD 3 ; Dima L. Diab (...) From the 1 Guideline Task Force Co-Chair, Professor of Medicine, Director, Loyola University Osteoporosis and Metabolic Bone Disease Center, Maywood, Illinois, 2 Guideline Task Force Co-Chair, Associate Clinical Professor, Weill-Cornell Medical College, Division Head and Service Chief, Endocrinology, Houston Methodist Hospital, Charles and Anne Duncan Centennial Clinical Academic Scholar in Endocrinology, Houston, Texas, 3 Professor of Medicine, Divisions of Endocrinology and Geriatrics, University

2020 American Association of Clinical Endocrinologists

5. AACE Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis

AACE Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis ENDOCRINE PRACTICE Vol 26 (Suppl 1) May 2020 1 Copyright © 2020 AACE Clinical Practice Guidelines AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/ AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS— 2020 UPDATE Pauline M. Camacho, MD, FACE 1 ; Steven M. Petak, MD, JD, FACP , FCLM, MACE, CCD 2 ; Neil Binkley, MD 3 ; Dima L (...) , 2020 From the 1 Guideline Task Force Co-Chair, Professor of Medicine, Director, Loyola University Osteoporosis and Metabolic Bone Disease Center, Maywood, Illinois, 2 Guideline Task Force Co-Chair, Associate Clinical Professor, Weill-Cornell Medical College, Division Head and Service Chief, Endocrinology, Houston Methodist Hospital, Charles and Anne Duncan Centennial Clinical Academic Scholar in Endocrinology, Houston, Texas, 3 Professor of Medicine, Divisions of Endocrinology and Geriatrics

2020 American Association of Clinical Endocrinologists

6. Romosozumab (Evenity) - treatment of severe osteoporosis

Romosozumab (Evenity) - treatment of severe osteoporosis 1 Published 09 November 2020 1 SMC2280 romosozumab 105mg solution for injection in pre- filled pen (Evenity®) UCB Pharma Ltd 9 October 2020 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission romosozumab (Evenity®) is accepted (...) for restricted use within NHSScotland. Indication under review: treatment of severe osteoporosis in postmenopausal women at high risk of fracture. SMC restriction: to use in patients who have experienced a fragility fracture and are at imminent risk of another fragility fracture (within 24 months). In a phase III study in post-menopausal women with osteoporosis who were at high risk of fracture, romosozumab for 12 months followed by an oral bisphosphanate reduced the risk of fractures compared with an oral

2020 Scottish Medicines Consortium

7. Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis : A Population-Based Cohort Study. (Abstract)

Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis : A Population-Based Cohort Study. Denosumab is effective for osteoporosis, but discontinuation leads to rapid reversal of its therapeutic effect.To estimate the risk for fracture among users of denosumab who delayed subsequent doses compared with users who received doses on time.Population-based cohort study.The Health Improvement Network U.K. primary care database, 2010 to 2019.Persons aged 45 years or older who

2020 Annals of Internal Medicine

8. Comparison of efficacy and safety of Chinese patent medicine in the treatment of postmenopausal osteoporosis ― A protocol for systematic review and network meta-analysis Full Text available with Trip Pro

Comparison of efficacy and safety of Chinese patent medicine in the treatment of postmenopausal osteoporosis ― A protocol for systematic review and network meta-analysis Inplasy Protocol 775 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols

9. The efficiency and safety of alendronate versus teriparatide for treatment glucocorticoid-induced osteoporosis: A meta-analysis and systematic review of randomized controlled trials Full Text available with Trip Pro

The efficiency and safety of alendronate versus teriparatide for treatment glucocorticoid-induced osteoporosis: A meta-analysis and systematic review of randomized controlled trials Inplasy Protocol 753 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols

10. Vitamin D Receptor Bsm I Polymorphism and Osteoporosis Risk in postmenopausal women: A Meta-Analysis from 42 Studies Full Text available with Trip Pro

Vitamin D Receptor Bsm I Polymorphism and Osteoporosis Risk in postmenopausal women: A Meta-Analysis from 42 Studies Vitamin D Receptor Bsm I Polymorphism and Osteoporosis Risk in postmenopausal women: A Meta-Analysis from 42 Studies | Research Square Browse Tools & Services Your Cart See the published version of this article at . This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior (...) to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research Vitamin D Receptor Bsm I Polymorphism and Osteoporosis Risk in postmenopausal women: A Meta-Analysis from 42 Studies JunLong Liao, Qiang Qin, YongSheng Zhou, RuPing Ma, HeChao Zhou, MaoRong Gu, Yunping Feng, BoYuan Wang, Ling Yang JunLong Liao Sixth Affiliated Hospital of Kunming

2020 Research Square

11. Management of osteoporosis and the prevention of fragility fractures

Management of osteoporosis and the prevention of fragility fractures Management of osteoporosis and the prevention of fragility fractures A national clinical guideline First published March 2015 Revised edition published June 2020 SIGN142Key to evidence statements and recommendations Levels of evidence 1 ++ High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 1 + Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias 1 – Meta (...) used by Scottish Intercollegiate Guidelines Network to produce clinical guidelines. The accreditation term is valid until 30 June 2020 and is applicable to guidance produced using the processes described in SIGN 50: a guideline developer’s handbook, 2019 edition (https://www.sign.ac.uk/assets/sign50_2019.pdf). More information on accreditation can be viewed at www.nice.org.uk/accreditationScottish Intercollegiate Guidelines Network Management of osteoporosis and the prevention of fragility

2020 SIGN

12. Physical fitness in older women with osteoporosis and vertebral fracture after a resistance and balance exercise programme: 3-month post-intervention follow-up of a randomised controlled trial Full Text available with Trip Pro

Physical fitness in older women with osteoporosis and vertebral fracture after a resistance and balance exercise programme: 3-month post-intervention follow-up of a randomised controlled trial Physical fitness in older women with osteoporosis and vertebral fracture after a resistance and balance exercise programme: 3-month post-intervention follow-up of a randomised controlled trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set (...) Permalink Copy Page navigation BMC Musculoskelet Disord Actions . 2020 Jul 18;21(1):471. doi: 10.1186/s12891-020-03495-9. Physical fitness in older women with osteoporosis and vertebral fracture after a resistance and balance exercise programme: 3-month post-intervention follow-up of a randomised controlled trial , , , , , Affiliations Expand Affiliations 1 Institute of Physiotherapy, Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway. bsugland@oslomet.no. 2 Institute

2020 EvidenceUpdates

13. Tai Chi on bone mineral density of postmenopausal osteoporosis: a protocol for systematic review and meta-analysis Full Text available with Trip Pro

Tai Chi on bone mineral density of postmenopausal osteoporosis: a protocol for systematic review and meta-analysis Inplasy Protocol 568 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols

14. What Factors Affect the Methodological and Reporting Quality of Clinical Practice Guidelines for Osteoporosis? Protocol for A Systematic Review Full Text available with Trip Pro

What Factors Affect the Methodological and Reporting Quality of Clinical Practice Guidelines for Osteoporosis? Protocol for A Systematic Review Inplasy Protocol 495 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols

15. Efficacy and Safety of Bisphosphonates Analogues in Persons with Osteoporosis after Spinal Cord Injury: a Systematic Review and Meta-Analysis of Randomized Controlled Trials Full Text available with Trip Pro

Efficacy and Safety of Bisphosphonates Analogues in Persons with Osteoporosis after Spinal Cord Injury: a Systematic Review and Meta-Analysis of Randomized Controlled Trials Inplasy Protocol 477 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols

16. Blood Lipid Levels in Patients with Osteopenia and Osteoporosis: A Systematic Review and Meta-Analysis Full Text available with Trip Pro

Blood Lipid Levels in Patients with Osteopenia and Osteoporosis: A Systematic Review and Meta-Analysis Blood Lipid Levels in Patients with Osteopenia and Osteoporosis: A Systematic Review and Meta-Analysis | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should (...) not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research Blood Lipid Levels in Patients with Osteopenia and Osteoporosis: A Systematic Review and Meta-Analysis Hang Zhao, An Song, Yong Li, Licui Qi, Chong Zheng, Luping Ren, Guangyao Song Hang Zhao hebei genral hospital An Song Hebei General Hospital Yong Li Hebei General Hospital Licui Qi Hebei General Hospital Chong Zheng Shijiazhuang third hospital Luping Ren

2020 Research Square

17. Teriparatide (Osnuvo) - osteoporosis

Teriparatide (Osnuvo) - osteoporosis Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012

2020 Health Canada - Drug and Health Product Register

18. The Effect of Qigong Wuqinxi for Osteopenia and Primary Osteoporosis: protocol for a systematic review and meta-analysis Full Text available with Trip Pro

The Effect of Qigong Wuqinxi for Osteopenia and Primary Osteoporosis: protocol for a systematic review and meta-analysis Inplasy Protocol 157 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review Protocols

19. Network meta analysis of four kinds of traditional Chinese fitness methods in the treatment of osteoporosis in the elderly Full Text available with Trip Pro

Network meta analysis of four kinds of traditional Chinese fitness methods in the treatment of osteoporosis in the elderly Inplasy Protocol 136 - INPLASY.COM International Platform of Registered Systematic Review and Meta-analysis Protocols Main Menu Share this: Copyright © 2021 INPLASY.COM Powered by INPLASY.COM

2020 INPLASY - International Platform of Registered Systematic Review Protocols

20. Vitamin D receptor (VDR) gene FokI, BsmI, ApaI, and TaqI polymorphisms and osteoporosis risk: a meta-analysis Full Text available with Trip Pro

Vitamin D receptor (VDR) gene FokI, BsmI, ApaI, and TaqI polymorphisms and osteoporosis risk: a meta-analysis Vitamin D receptor (VDR) gene Fok I, Bsm I, Apa I, and Taq I polymorphisms and osteoporosis risk: a meta-analysis | Egyptian Journal of Medical Human Genetics | Full Text Search Search all SpringerOpen articles Search Vitamin D receptor (VDR) gene Fok I, Bsm I, Apa I, and Taq I polymorphisms and osteoporosis risk: a meta-analysis , & volume 21 , Article number: 15 ( 2020 ) 690 Accesses (...) 1 Citations Abstract Background Osteoporosis is a disease of the bones in which the density of the bones decreases. The prevalence of this disease greatly varies in different populations of the world. Numerous studies have been investigated VDR gene polymorphisms as osteoporosis risk in different ethnic groups. In present meta-analysis, the aim is to find out the role of VDR gene polymorphisms ( Fok I, Bsm I, Apa I, and Taq I) in osteoporosis risk. Methods Suitable case-control studies

2020 Egyptian Journal of Medical Human Genetics